DENTAL PRODUCTS ADVISORY PANEL CHAIR RESIGNS FOLLOWING RELEASE OF IG PROBE; NOV. 3-4 PANEL MEETING WILL REVISIT UNCLASSIFIED MUSCLE MONITORING DEVICES
This article was originally published in The Gray Sheet
Executive Summary
Charles Bertolami, DDS, University of San Francisco voluntarily resigned as chairman of FDA's Dental Products Advisory Panel following an investigation by the HHS Office of the Inspector General, according to a letter from FDA Deputy Commissioner for External Affairs Sharon Smith Holston to Rep. Joe Barton (R-Tex.). Manufacturers' complaints regarding the panel chair's failure to abide by appropriate procedure at the Dental Panel's Oct. 13, 1994 meeting on muscle monitoring devices prompted the investigation.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.